Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years
Clinical Infectious Diseases · 04.02.2026 · 81 (6) · e708-e716
DOI: 10.1093/cid/ciaf292 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 04.06.2025. Verfasst von Erick F Mayer und 20 weiteren Autor:innen. Beteiligte Einrichtung: Moderna, Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Immunogenicity, Vaccine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) is a significant health risk for adults aged 18–59 years with chronic medical conditions.
Methods
This ongoing, randomized, double-blind phase 3 trial evaluates safety and immunogenicity of the RSV vaccine, mRNA-1345, in adults aged 18–59 years at increased risk for RSV-associated lower respiratory tract disease (LRTD). Participants received a single 50-µg (licensed dose) or 30-µg dose. Co-primary immunogenicity objectives were to demonstrate noninferiority of day 29 RSV-A/B neutralizing antibody (nAb) geometric mean titers (GMTs) for the 50-μg dose compared with those observed in adults aged ≥60 years from the phase 3 pivotal efficacy trial. The other primary objective was to evaluate safety and tolerability.
Results
A total of 999 participants received mRNA-1345 (50 µg, n = 502; 30 µg, n = 497). Most solicited adverse reactions (ARs) were mild to moderate with a median duration of 2 days. Day 29 nAb GMTs in the 50-µg group met noninferiority criteria: RSV-A GMT ratio (GMR), 1.2 (95% confidence interval [CI], 1.1–1.3); RSV-B GMR, 1.1 (95% CI, 1.0–1.2). Noninferiority was also demonstrated for seroresponse rate differences: RSV-A, 11.8% (95% CI, 7.8–15.5); RSV-B, 10.8% (95% CI, 5.9–15.6). Immune responses were consistent across subgroups and remained above baseline through day 181.
Conclusions
In adults aged 18–59 years at increased risk for RSV-LRTD, a 50-µg dose of mRNA-1345 was well tolerated and elicited RSV-A and RSV-B nAb responses noninferior to those observed in older adults in the pivotal study, supporting inference of efficacy in this population. Clinical Trials Registration NCT06067230
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Moderna, Inc, Cambridge, Massachusetts, USA.
- University of Rochester School of Medicine, Rochester, New York, USA.
- Department of Clinical Research, Layton Medical Centre, Blackpool, United Kingdom.
- Department of Family Medicine and Emergency Medicine, Colchester Research Group, Truro, Nova Scotia, Canada.
- Indago Research, Hialeah, Florida, USA.
- Cambridge ID & Immunology Consulting, LLC, Somerville, Massachusetts, USA.
ORCID-Profile: Erick F Mayer, Ann R Falsey, Eleanor Wilson, Frances Priddy
Förderung
- Moderna, Inc
Zitieren
APA
Mayer, E. F., Falsey, A. R., Clark, R., Ferguson, M., Cardona, J., She, F., Jones, B., Reuter, C., Collins, A., Mannan, A., Kapoor, A., Slobod, K., Stoszek, S. K., Du, J., Mou, J., Lan, L., Zhou, H., Wilson, E., Goswami, J., …, & Priddy, F. (2026). Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years. Clinical Infectious Diseases, 81(6), e708-e716. https://doi.org/10.1093/cid/ciaf292
Vancouver
Mayer EF, Falsey AR, Clark R, Ferguson M, Cardona J, She F, et al. Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years. Clinical Infectious Diseases. 2026;81(6):e708-e716. doi:10.1093/cid/ciaf292
BibTeX
@article{Mayer2026,
author = {Mayer, Erick F and Falsey, Ann R and Clark, Rebecca and Ferguson, Murdo and Cardona, Jose and She, Fahua and Jones, Barbara and Reuter, Caroline and Collins, Avi and Mannan, Anisha and Kapoor, Archana and Slobod, Karen and Stoszek, Sonia K and Du, Jiejun and Mou, Jenni and Lan, Lan and Zhou, Honghong and Wilson, Eleanor and Goswami, Jaya and Das, Rituparna and Priddy, Frances},
title = {Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18–59 Years},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {81},
number = {6},
pages = {e708--e716},
doi = {10.1093/cid/ciaf292}
}
EUVIMED